Gland Pharma Share Price Jumps 12% As Investors Cheer Results 

Mumbai, August 11: Shares of Gland Pharma surged nearly 12% in Tuesday’s trade, making it the top gainer on the Nifty Midcap 100, after the drugmaker delivered a strong June-quarter performance. The positive reaction was further supported by brokers upgrading the stock to ‘Buy’ and raising target price, signalling more than 25% potential upside from Monday’s closing level. 

Strong Q1 Performance 

Gland Pharma reported a 47.1% year-on-year increase in consolidated net profit to ₹317 crore for the April-June quarter, compared with ₹215 crore in the corresponding period last year. Revenue rose 19.6% to ₹1,800.2 crore from ₹1,505.6 crore in Q1 FY26. 

The improvement also extended to operating profitability. EBITDA increased 33.1% year-on-year to ₹489.2 crore, while the EBITDA margin expanded to 27.2% from 24.4% a year earlier. The company’s profit-after-tax margin improved by around 330 basis points during the quarter. 

US Business Drives Growth 

The stock jumped as results inspired an optimistic outlook among investors. Source: NSE 

Brokers highlighted the company’s strong performance in the U.S. market as a key reason behind their more optimistic outlook. Gland Pharma’s U.S. business grew 32% year-on-year during the quarter, prompting the brokerages to raise FY27 growth expectation to potentially 15% in constant-currency terms from earlier estimate of 12-13%. 

The brokerages also pointed to a new contract development and manufacturing organisation (CDMO) agreement and the in-licensing of a differentiated product with a large addressable market as additional growth catalysts. 

Cenexi Losses Easing 

Brokers said several of the challenges that had weighed on Gland Pharma’s performance appear to be easing. In particular, the brokerages expect Cenexi, the company’s European contract manufacturing business, to move towards breakeven. 

New contract wins and Gland Pharma’s expansion into complex products could provide additional growth momentum, while improving performance at Cenexi could support overall profitability. 

Stock Outlook 

Gland Pharma has already gained around 67% so far in 2026, significantly outperforming the Nifty 50, which has declined around 6% over the same period. 

Brokers’ target price implies further upside from the current levels, with the brokerages arguing that the company’s earnings trajectory and growth prospects have improved. Investors will now track whether the strong U.S. performance, new CDMO contracts and recovery at Cenexi can sustain the company’s earnings momentum in the coming quarters. 

Source

•  https://www.nseindia.com/get-quote/equity/GLAND/Gland-Pharma-Limited